##ANALYSISTYPE=SOMATIC_PAIR
##PIPELINE=megSAP 2025_10-79-gaaed1599
##GENOME_BUILD=GRCh38
##CREATION_DATE=2024-09-04
##CALLING_DATE=2020-09-01
##FILTER=all-unknown=Allele unknown
##FILTER=depth-nor=Sequencing depth in normal is too low (< 20)
##FILTER=depth-tum=Sequencing depth in tumor is too low (< 20)
##FILTER=freq-nor=Allele frequency in normal > 0.17 * allele frequency in tumor
##FILTER=freq-tum=Allele frequency in tumor < 0.05
##FILTER=LowDepth=Tumor or normal sample read depth at this locus is below 2
##FILTER=LowEVS=Somatic Empirical Variant Score (SomaticEVS) is below threshold
##FILTER=lt-3-reads=Less than 3 supporting tumor reads
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=special-chromosome=Special chromosome
##SAMPLE=<ID=GS110168_03,Gender=n/a,ExternalSampleName=SL-ALL-1; Pat7;QA007004DQ,IsTumor=yes,IsFFPE=no,DiseaseGroup=Neoplasms,DiseaseStatus=Affected>
##SAMPLE=<ID=GS110169_03,Gender=n/a,ExternalSampleName=SL-FB-1; Pat7;QA007011D9,IsTumor=no,IsFFPE=no,DiseaseGroup=Neoplasms,DiseaseStatus=Affected>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), quality divided by depth (QD), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous/hemizygous case count of gnomAD project (genome data).
##DESCRIPTION=gnomAD_het=Heterozygous allele count of the gnomAD project (genome data).
##DESCRIPTION=gnomAD_wt=Wildtype allele count of the gnomAD project (genome data).
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=AlphaMissense=AlphaMissense pathogenicity score. Deleterious threshold > 0.564.
##DESCRIPTION=MaxEntScan=MaxEntScan reference score and alternate score for (1) native splice site, (2) acceptor gain and (3) donor gain. Comma-separated list if there are different predictions for several transcripts.
##DESCRIPTION=SpliceAI=SpliceAI prediction. These include delta scores (DS) and delta positions (DP) for acceptor gain (AG), acceptor loss (AL), donor gain (DG), and donor loss (DL). Format: GENE|DS_AG|DS_AL|DS_DG|DS_DL|DP_AG|DP_AL|DP_DG|DP_DL.
##DESCRIPTION=PubMed=PubMed ids to publications on the given variant.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD (tumor-normal).
##DESCRIPTION=NGSD_som_p=Project names containing this somatic variant in the NGSD (tumor-normal).
##DESCRIPTION=NGSD_som_to_c=Somatic variant count in the NGSD (tumor-only).
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_mosaic=Mosaic variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample GS110168_03).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample GS110168_03).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample GS110169_03).
##DESCRIPTION=normal_dp=Normal depth (Sample GS110169_03).
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	quality	gene	variant_type	coding_and_splicing	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	gnomAD	gnomAD_sub	gnomAD_hom_hemi	gnomAD_het	gnomAD_wt	phyloP	CADD	REVEL	AlphaMissense	MaxEntScan	SpliceAI	PubMed	NGSD_som_c	NGSD_som_p	NGSD_som_to_c	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_mosaic	NGSD_group	classification	classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT
chr10	68722505	68722505	A	G	0.1975	1209	0.0000	670		QUAL=567															6.7200	23.40						0		0			0	0	0	0 / 0					CCAR1 (inh=n/a oe_syn=0.86 oe_mis=0.58 oe_lof=0.12)								
chr14	104780214	104780214	C	T	0.4225	1114	0.0007	1359		QUAL=1948						13983 [uncertain significance DISEASE=Hepatocellular carcinoma,Osteosarcoma,Transitional cell carcinoma of the bladder,Lung adenocarcinoma,Small cell lung cancer,Non-small cell lung cancer,Squamous cell lung carcinoma,Neoplasm of the breast,Neoplasm of the thyroid gland,Neoplasm of ovary,Prostate neoplasm,Neoplasm of the large intestine,Squamous cell carcinoma of the head and neck,Malignant melanoma of skin,Uterine cervical neoplasms,Meningeal Neoplasms,Adenocarcinoma of prostate,Carcinoma of colon,Proteus syndrome,Adenocarcinoma of stomach,Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation,Breast adenocarcinoma,Cowden syndrome 6];	CM1611160 [CLASS=DM MUT=ALT PHEN="Epidermal naevus with underlying overgrowth" GENE=AKT1];								7.8110	25.60						9	SomaticAndTreatment	0			0	0	n/a	0 / 0						AKT1	COSV62571334	breast/carcinoma/NS=61/3743=1.63%;bone/Overgrowth_syndrome/Proteus_syndrome=14/20=70%;thyroid/carcinoma/anaplastic_carcinoma=12/642=1.87%;meninges/meningioma/meningothelial=17/325=5.23%;NS/carcinoma/of_unknown_primary=4/209=1.91%;soft_tissue/desmoid_tumour-fibromatosis/NS=8/256=3.13%;breast/carcinoma/hormone_receptor-positive_carcinoma=9/328=2.74%;meninges/meningioma/transitional=5/259=1.93%;soft_tissue/Overgrowth_syndrome/Proteus_syndrome=7/10=70%;skin/Overgrowth_syndrome/Proteus_syndrome=51/60=85%;breast/carcinoma/luminal_A_carcinoma=4/58=6.9%;breast/carcinoma/ER-positive_carcinoma=57/1470=3.88%;breast/carcinoma/ER-PR-positive_carcinoma=17/364=4.67%;breast/carcinoma/ductal_carcinoma=114/3743=3.05%;prostate/carcinoma/NS=12/1135=1.06%;urinary_tract/carcinoma/transitional_cell_carcinoma=17/1082=1.57%;breast/carcinoma/lobular_carcinoma=26/503=5.17%;breast/carcinoma/basal_(triple-negative)_carcinoma=7/553=1.27%;endometrium/carcinoma/endometrioid_carcinoma=26/954=2.73%;meninges/meningioma/NS=40/427=9.37%	colon=0.0004;thyroid=0.0494;breast=5.59e-47;endometrioid=3.59e-15	1	ENST00000349310:p.Glu17Lys	149	148
chr21	10541002	10541002	T	C	0.3333	18	0.0000	10	depth-tum;depth-nor;off-target	QUAL=18										0.30912		0,			0.0260	3.31						2	I17R006,eMed-HCC	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					TPTE (inh=n/a oe_syn=1.04 oe_mis=1.24 oe_lof=1.09)								
chr21	10473061	10473061	C	T	0.1739	46	0.0286	35	off-target	QUAL=44															2.2780	9.02						0		0			0	1393	n/a	0 / 68					BAGE2 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr21	30371921	30371921	C	A	0.4340	106	0.0000	104		QUAL=216															0.4500	16.55						1	Leuk	0			0	0	n/a	0 / 0					KRTAP13-2 (inh=n/a oe_syn=1.28 oe_mis=1.23 oe_lof=1.71):MIR4327 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr21	32601784	32601784	-	T	1.0000	3	0.0000	9	depth-tum;depth-nor;off-target	QUAL=4										0.00304		0,				0.64						1	eMed-HCC	0			0	5	n/a	0 / 1					CFAP298 (inh=AR oe_syn=1.16 oe_mis=0.92 oe_lof=0.65)								
chr21	46317936	46317936	G	T	0.7857	14	0.0000	6	depth-tum;depth-nor;off-target	QUAL=18															-0.7170	13.98						0		0			0	0	0	0 / 0					C21ORF58 (inh=n/a oe_syn=1.23 oe_mis=0.92 oe_lof=1.15)								
